ONCOZ — Oncozenge AB Share News
0.000.00%
Last trade - 00:00- SEK89.74m
- SEK96.49m
- SEK2.66m
Brief: Pharmanovia Discontinues Its Due Diligence Process With Oncozegne
Brief: Oncozenge July-Sept Operating Loss Narrows To SEK 1.8 Mln
Brief: Oncozenge Agrees SEK 10 Mln Bridge Financing With Linc AB
Brief: Oncozenge Intends To Enter Partnership With Pharmanovia For Commercialization Of Bupizenge
Brief: Oncozenge H1 Operating Loss Narrows To Sek 4.4 Mln
Brief: Oncozenge Says Ongoing Studies For Bupizenge™ Show Positive Results
Brief: Oncozenge Explores Strategic Options For Bupizenge™ In China
Brief: Oncozenge Files Patent Application For Strengthened IP Protection For Bupizenge
Brief: Ensysce Biosciences And Oncozenge Sign LoI For Development Of Bupizenge In The U.S.
Brief: Oncozenge Updates On Taking BupiZenge To Market
Brief: New Formulation Of Oncozenge's Drug Candidate BupiZenge Is Clean
Brief: Oncozenge Q3 Operating Loss Widens To SEK 4.2 Mln
Brief: Oncozenge Appoint Michael Owens As New CFO
Brief: OncoZenge Appoints Stian Kildal As New CEO
Brief: Daniel Ehrenstråhle Elected As Chairman of Oncozenge Board
Brief: OncoZenge CEO, Chair Of Board Resign After EGM
Brief: OncoZenge Pauses Development Of BupiZenge
Brief: Oncozenge Q1 Net Loss Narrows To SEK 4.1 Mln
Brief: Oncozenge Gets Response From Regulatory Authorities In Europe, USA